开云app官网登录入口网页版-官方正版

#阿达木单抗#

5篇内容 | 3511人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2224400, encodeId=6e312224400e4, content=<a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a> <a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a> <a href='/topic/show?id=1cac118e8660' target=_blank style='color:#2F92EE;'>#胃肠道穿孔（GIP）#</a>, objectTitle=Arthritis Rheumatol：JAK抑制剂和阿达木单抗治疗类风湿性疾病患者的胃肠道穿孔发生率会有明显差异吗？, objectType=article, longId=842036, objectId=c27984203698, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240731/1722389920924_92910.jpg, objectUrl=/article/show_article.do?id=c27984203698, replyNumber=0, likeNumber=13, createdTime=2024-09-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c27984203698, moduleTitle=Arthritis Rheumatol：JAK抑制剂和阿达木单抗治疗类风湿性疾病患者的胃肠道穿孔发生率会有明显差异吗？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c27984203698)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209130, encodeId=62f4220913092, content=<a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a> <a href='/topic/show?id=fb63105e921d' target=_blank style='color:#2F92EE;'>#司库奇尤单抗#</a> <a href='/topic/show?id=81771153436c' target=_blank style='color:#2F92EE;'>#放射学轴性脊柱关节炎#</a>, objectTitle=EULAR:两年脊柱的放射学进展，司库奇尤单抗和阿达木单抗之间没有显著差异, objectType=article, longId=775510, objectId=d8ede755100e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/conference-with-doctors-in-medical-aprons-PT29AAG.jpg, objectUrl=/article/show_article.do?id=d8ede755100e, replyNumber=0, likeNumber=54, createdTime=2024-06-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=d8ede755100e, moduleTitle=EULAR:两年脊柱的放射学进展，司库奇尤单抗和阿达木单抗之间没有显著差异, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d8ede755100e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2180819, encodeId=db07218081920, content=<a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a> <a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a> <a href='/topic/show?id=8eeb8e122c6' target=_blank style='color:#2F92EE;'>#英夫利昔单抗#</a>, objectTitle=IBD：阿达木单抗和英夫利西单抗治疗儿童克罗恩病的持久性, objectType=article, longId=809011, objectId=c6d0809011c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679866876965_4754896.webp, objectUrl=/article/show_article.do?id=c6d0809011c7, replyNumber=0, likeNumber=114, createdTime=2024-01-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c6d0809011c7, moduleTitle=IBD：阿达木单抗和英夫利西单抗治疗儿童克罗恩病的持久性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c6d0809011c7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2121891, encodeId=b37c2121891ed, content=<a href='/topic/show?id=698381e44dc' target=_blank style='color:#2F92EE;'>#肠道超声#</a>下<a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a>治疗肠腔狭窄<a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a>的疗效！肠道超声值得推广, objectTitle=ECCO 2023 | 肠道超声下阿达木单抗治疗肠腔狭窄克罗恩病的疗效：随机试验STRIDENT, objectType=article, longId=763610, objectId=43dbe6361089, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/diagnostic-form-in-hospital-conceptual-image-7JAH3GT.jpg, objectUrl=/article/show_article.do?id=43dbe6361089, replyNumber=0, likeNumber=172, createdTime=2023-03-26, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=43dbe6361089, moduleTitle=ECCO 2023 | 肠道超声下阿达木单抗治疗肠腔狭窄克罗恩病的疗效：随机试验STRIDENT, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=43dbe6361089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2121003, encodeId=f40a212100364, content=<a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a>治疗<a href='/topic/show?id=c5c510568510' target=_blank style='color:#2F92EE;'>#肠腔狭窄#</a><a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a>, objectTitle=ECCO 2023 | 肠道超声下阿达木单抗治疗肠腔狭窄克罗恩病的疗效：随机试验STRIDENT, objectType=article, longId=763610, objectId=43dbe6361089, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/diagnostic-form-in-hospital-conceptual-image-7JAH3GT.jpg, objectUrl=/article/show_article.do?id=43dbe6361089, replyNumber=0, likeNumber=150, createdTime=2023-03-22, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=43dbe6361089, moduleTitle=ECCO 2023 | 肠道超声下阿达木单抗治疗肠腔狭窄克罗恩病的疗效：随机试验STRIDENT, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=43dbe6361089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2117621, encodeId=89ad211e6212e, content=<a href='/topic/show?id=d38b501864f' target=_blank style='color:#2F92EE;'>#强直性脊柱炎#</a>（AS）传统治疗策略仅限于非甾体抗炎药、糖皮质激素等药物。TNFi已被证明能有效改善AS患者的腰椎前凸畸形。目前可用于临床治疗AS的TNFi主要包括<a href='/topic/show?id=8eeb8e122c6' target=_blank style='color:#2F92EE;'>#英夫利昔单抗#</a>（infliximab，IFX）、<a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a>（adalimumab，ADA）、<a href='/topic/show?id=4f465380215' target=_blank style='color:#2F92EE;'>#戈利木单抗#</a>（golimumab，GOL）以及<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>（Enbrel，ETN）等。, objectTitle=浅谈强直性脊柱炎相关生物制剂和小分子靶向药治疗进展, objectType=article, longId=761626, objectId=d026e61626ad, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230304/1677928811259_5295905.jpg, objectUrl=/article/show_article.do?id=d026e61626ad, replyNumber=0, likeNumber=130, createdTime=2023-03-05, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d026e61626ad, moduleTitle=浅谈强直性脊柱炎相关生物制剂和小分子靶向药治疗进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d026e61626ad)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2089215, encodeId=cb5a20892158b, content=我国自主研发的<a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a><a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a><a href='/topic/show?id=275593112a' target=_blank style='color:#2F92EE;'>#IBI303#</a>，在治疗<a href='/topic/show?id=d38b501864f' target=_blank style='color:#2F92EE;'>#强直性脊柱炎#</a>的疗效、安全性上可比肩国外<a href='/topic/show?id=3be83e20383' target=_blank style='color:#2F92EE;'>#原研药#</a>，国内的强直性脊柱炎患者未来将有更多用药选择。<a href='/topic/show?id=aa7d104e95fd' target=_blank style='color:#2F92EE;'>#徐沪济#</a>, objectTitle=Lancet Rheum：中国研究成果“IBI303”登上《柳叶刀·风湿病学》封面推介, objectType=article, longId=179005, objectId=761a1e90059c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201909/20190905222150963.jpg, objectUrl=/article/show_article.do?id=761a1e90059c, replyNumber=0, likeNumber=148, createdTime=2022-09-20, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=761a1e90059c, moduleTitle=Lancet Rheum：中国研究成果“IBI303”登上《柳叶刀·风湿病学》封面推介, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=761a1e90059c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=953885, encodeId=ba9a953885e7, content=<a href='/topic/show?id=292c18148b3' target=_blank style='color:#2F92EE;'>#upadacitinib#</a>优于<a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a>？当然，<a href='/topic/show?id=5a64966325c' target=_blank style='color:#2F92EE;'>#银屑病关节炎#</a>中，TNF只是其中一个机制, objectTitle=NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗, objectType=article, longId=209559, objectId=afa5209559ff, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202144/1617498907332_2051781.jpg, objectUrl=/article/show_article.do?id=afa5209559ff, replyNumber=0, likeNumber=222, createdTime=2021-04-05, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afa5209559ff, moduleTitle=NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=afa5209559ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

阿达木单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#阿达木单抗# #JAK抑制剂# #胃肠道穿孔（GIP）#

Arthritis Rheumatol：JAK抑制剂和阿达木单抗治疗类风湿性疾病患者的胃肠道穿孔发生率会有明显差异吗？

2024-09-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#阿达木单抗# #司库奇尤单抗# #放射学轴性脊柱关节炎#

EULAR:两年脊柱的放射学进展，司库奇尤单抗和阿达木单抗之间没有显著差异

2024-06-09发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#克罗恩病# #阿达木单抗# #英夫利昔单抗#

IBD：阿达木单抗和英夫利西单抗治疗儿童克罗恩病的持久性

2024-01-11发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#肠道超声#下#阿达木单抗#治疗肠腔狭窄#克罗恩病#的疗效！肠道超声值得推广

ECCO 2023 | 肠道超声下阿达木单抗治疗肠腔狭窄克罗恩病的疗效：随机试验STRIDENT

2023-03-26发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#阿达木单抗#治疗#肠腔狭窄##克罗恩病#

ECCO 2023 | 肠道超声下阿达木单抗治疗肠腔狭窄克罗恩病的疗效：随机试验STRIDENT

2023-03-22发表于上海

lifestar (审核中...)

前往app查看评论内容

全文收起 #强直性脊柱炎#（AS）传统治疗策略仅限于非甾体抗炎药、糖皮质激素等药物。TNFi已被证明能有效改善AS患者的腰椎前凸畸形。目前可用于临床治疗AS的TNFi主要包括#英夫利昔单抗#（infliximab，IFX）、#阿达木单抗#（adalimumab，ADA）、#戈利木单抗#（golimumab，GOL）以及#依那西普#（Enbrel，ETN）等。

浅谈强直性脊柱炎相关生物制剂和小分子靶向药治疗进展

2023-03-05发表于上海

小小医者 (审核中...)

前往app查看评论内容

我国自主研发的#阿达木单抗##生物类似药##IBI303#，在治疗#强直性脊柱炎#的疗效、安全性上可比肩国外#原研药#，国内的强直性脊柱炎患者未来将有更多用药选择。#徐沪济#

Lancet Rheum：中国研究成果“IBI303”登上《柳叶刀·风湿病学》封面推介

2022-09-20

病毒猎手 (审核中...)

前往app查看评论内容

#upadacitinib#优于#阿达木单抗#？当然，#银屑病关节炎#中，TNF只是其中一个机制

NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗

2021-04-05

科室
- - 订阅+
  - 更多科室
工具
服务